Although MIF levels were not significantly different between patients with early (Stage I/II) and late-stage (Stage III/IV) ovarian cancer (207), higher MIF levels were associated with poor overall survival in recurrent cases, even though MIF had no correlation with progression-free survival (208). The gene discussed is MIF; the disease is ovarian cancer.